CG Oncology, Inc. (CGON) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $1.55B; Retained Earnings (Accumulated Deficit)USD $-518.23M; Stockholders' Equity Attributable to ParentUSD $1.03B.
- 2026-03-31: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $1.53B; Retained Earnings (Accumulated Deficit)USD $-439.18M; Stockholders' Equity Attributable to ParentUSD $1.09B.
- 2025-12-31: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $1.13B; Retained Earnings (Accumulated Deficit)USD $-378.98M; Stockholders' Equity Attributable to ParentUSD $752.60M.
- 2025-09-30: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $1.03B; Retained Earnings (Accumulated Deficit)USD $-337.67M; Stockholders' Equity Attributable to ParentUSD $687.64M.
CG Oncology, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|
| 2026-06-30 | $9.00K | $1.55B | $-518.23M | $1.03B | 3 month · $14.33M |
| 2026-03-31 | $9.00K | $1.53B | $-439.18M | $1.09B | 3 month · $6.47M |
| 2025-12-31 | $8.00K | $1.13B | $-378.98M | $752.60M | 12 month · $26.68M |
| 2025-09-30 | $8.00K | $1.03B | $-337.67M | $687.64M | 3 month · $7.33M |
| 2025-06-30 | $8.00K | $964.21M | $-293.86M | $670.36M | 3 month · $7.01M |
| 2025-03-31 | $8.00K | $957.18M | $-252.43M | $704.76M | 3 month · $5.15M |
| 2024-12-31 | $8.00K | $951.35M | $-217.98M | $733.38M | 12 month · $11.40M |
| 2024-09-30 | $7.00K | $722.95M | $-186.18M | $536.77M | 3 month · $2.65M |
| 2024-06-30 | $7.00K | $718.13M | $-165.78M | $552.36M | 3 month · $2.25M |
| 2024-03-31 | $7.00K | $715.81M | $-146.87M | $568.94M | 3 month · $1.52M |
| 2023-12-31 | (m) | $6.84M | $-129.94M | $-123.10M | 12 month · $1.53M |
| 2023-09-30 | (m) | (m) | (m) | $-107.58M | 3 month · $394.00K |
| 2023-06-30 | (m) | (m) | (m) | $-97.39M | 3 month · $177.00K |
| 2023-03-31 | (m) | (m) | (m) | $-86.12M | 3 month · $179.00K |
| 2022-12-31 | (m) | (m) | (m) | $-77.69M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |